NCT05413850 2026-04-13
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Blue Earth Therapeutics Ltd
Phase 1/2 Recruiting
Clinical Trials
7 trialsNCT06517719 2026-04-13
Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer
Novartis
Recruiting
NCT06531499 2025-12-31
RADIODOSE
Novartis
Phase 1 Recruiting
NCT06320067 2025-09-26
STAMPEDE2
University College, London
Phase 3 Recruiting
NCT06520345 2025-07-10
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT05803941 2025-04-24
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Novartis
Phase 4 Recruiting
NCT06449781 2025-02-10
PSMA-ADJUVO
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Recruiting